About AI in AAV & Gene Therapy Vector Development — Design, Process, Analytics, CMC Documentation & Regulatory Writing | Advanced Therapies Workshops | #EGeneCell 2026 

Join gene therapy consultants, AAV platform experts, and regulatory writing specialists for a focused workshop dedicated to the practical, non-hyped use of artificial intelligence across the AAV and gene therapy development lifecycle.

This workshop closes the Advanced Therapies Workshop Series with a forward-looking, hands-on session on where AI genuinely accelerates vector development today — and where it doesn't. From construct design and process optimisation to analytics, and now extending into CMC 

documentation and regulatory writing, participants leave with a realistic view of what AI tools can do for their programs right now.

Why Attend?

• AI-Driven Vector Design — see how AI tools are being used to design, screen, and de-risk AAV constructs clinically, regulatorily, and commercially
• AI in Process & Analytics — understand where machine learning is genuinely improving process development and analytical workflows in AAV manufacturing today
• AI in CMC Documentation & Regulatory Writing — explore practical use cases for AI in drafting, structuring, and quality-checking CMC sections and regulatory submissions
• Separating Hype from Reality — get a grounded, practitioner's view of which AI applications are ready for real programs and which are still aspirational
• Live Interactive Q&A — bring your own AI-in-CGT questions to an open discussion with a practising gene therapy consultant

Industry Trends, Pain Points & Critical Issues

• AI Hype Outpacing Practical Application — many organisations are under pressure to adopt AI tools without a clear view of where they add genuine value in CGT development
• CMC and Regulatory Writing Remain Manual and Slow — drafting and quality-checking CMC documentation is still one of the most time- and resource-intensive parts of ATMP development
• Vector Design Cycles Remain Long and Costly — iterative, trial-and-error AAV construct design continues to slow programs and inflate development costs
• Limited Practitioner-Level Guidance — most AI-in-biotech content is written by technologists rather than people who have applied it inside gene therapy programs

What to Expect

• Expert-Led, Practitioner-Style Sessions — learn directly from a gene therapy consultant who applies AI tools in AAV programstoday, not a generic AI vendor pitch
• Two Focused Deep Dives — AI in vector design, process and analytics; and AI in CMC documentation and regulatory writing
• Live Interactive Q&A — an open discussion session to bring your own questions on where AI fits in your program
• Live Expert Q&A & Takeaways — leave with a grounded view of which AI applications are ready to use now and which are still emerging

Join Us

The AI in AAV & Gene Therapy Vector Development — Design, Process, Analytics, CMC Documentation & Regulatory Writing | Advanced Therapies Workshops 2026 closes the series with a clear-eyed look at where artificial intelligence is genuinely changing AAV and gene therapy development — from the bench to the regulatory submission. If your team is evaluating where AI fits into vector design, process development, analytics, or CMC and regulatory writing, this workshop will give you a practical, non-hyped starting point.

Secure your place at #EGeneCell 2026 and be part of the community shaping how AI is actually used in advanced therapy development.